Pasithea Therapeutics Corp./$KTTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
Ticker
$KTTA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
4
ISIN
US70261F2020
Website
KTTA Metrics
BasicAdvanced
$6.6M
-
-$9.80
0.34
-
Price and volume
Market cap
$6.6M
Beta
0.34
52-week high
$3.79
52-week low
$0.79
Average daily volume
9.3M
Financial strength
Current ratio
3.84
Quick ratio
3.349
Management effectiveness
Return on assets (TTM)
-46.84%
Return on equity (TTM)
-82.81%
Valuation
Price to book
0.18
Price to tangible book (TTM)
0.53
Price to free cash flow (TTM)
-0.097
Growth
Earnings per share change (TTM)
-30.10%
3-year earnings per share growth (CAGR)
29.49%
KTTA News
AllArticlesVideos
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
GlobeNewsWire·1 week ago
Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases
GlobeNewsWire·3 weeks ago
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pasithea Therapeutics Corp. stock?
Pasithea Therapeutics Corp. (KTTA) has a market cap of $6.6M as of June 09, 2025.
What is the P/E ratio for Pasithea Therapeutics Corp. stock?
The price to earnings (P/E) ratio for Pasithea Therapeutics Corp. (KTTA) stock is 0 as of June 09, 2025.
Does Pasithea Therapeutics Corp. stock pay dividends?
No, Pasithea Therapeutics Corp. (KTTA) stock does not pay dividends to its shareholders as of June 09, 2025.
When is the next Pasithea Therapeutics Corp. dividend payment date?
Pasithea Therapeutics Corp. (KTTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Pasithea Therapeutics Corp.?
Pasithea Therapeutics Corp. (KTTA) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.